Back

Johnson & Johnson’s RYBREVANT combination extends survival to 34.3 months

Verifying
  • Johnson & Johnson reported final PAPILLON survival results for first-line RYBREVANT plus chemotherapy.
  • Median overall survival was 34.3 months versus 27.9 months with chemotherapy alone.
  • Seventy-six percent of eligible chemotherapy recipients crossed over to RYBREVANT after progression.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.